VEGFA and frontotemporal dementia: In particular, this post-hoc analysis of the SUNLIGHT trial showed that patients who never received anti-VEGF had mOS of 7.4 months for the FTD/TPI alone and 16.4 months for the combination; in patients who had received anti-VEGF only in the first line, mOS was 7.2 (monotherapy) and 10.4 (combination).